Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Welcome, everyone, and thank you for joining this investor webcast. My name is Megan Richards. I'm the Vice President of Investor Relations, Communications, and Portfolio Strategy, and I will be moderating the session today. Next slide. We refer to the typical investment disclaimers. Today you will hear from VICORE PHARMA's Chief Executive Officer, Ahmed Mousa, and our Chief Financial Officer, as they will spend some time walking through the recent news from VICORE PHARMA. And we will then open up the call for Q&A. So with that, I will turn it over to Ahmed Mousa.
Wonderful. Thank you, Megan, and thank you all for joining. As Megan mentioned, I'll provide some background, uh, discuss the case for using Angiotensin II type 2 receptor agonists. Then I'll talk about the Phase 2b ASPIRE trial that we've announced today that we've initiated. I'll turn it over to Hans to talk a little bit about the transaction. We've also announced the structure today, and then we'll be very happy to take questions via phone and via chat as well. So at the outset, right, just to recap really on what we're trying to achieve at the core and what we're spending as a high priority, in terms of our time, our resources, and our efforts, is the advancement of buloxibutid, a potentially transformational therapy for IPF? Uh, moving forward towards, you know, approval. And I think the case comes in three pillars. First is an upstream mechanism of action with an incredibly strong preclinical and translational data set. Buloxibutid has a mechanism that targets the source of the disease, where it agonizes and activates a tissue repair system in the alveolar epithelial stem or progenitor cells, allowing for the replenishment of the epithelium in the air sacs. Um, and this is quite distinct from the other ways of treating IPF that are seen in the standard of care and emerging standard of care, which focus solely on blocking the fibrosis further downstream. Instead, the Viper mechanism of action allows us to address both the injury at the center or the inception of the disease. You can then also have a resolution of the fibrosis further downstream. So that's really the first pillar of this case, and this disease-modifying mechanism that can repair the epithelium and resolve the fibrosis is then evident in the Phase 2b dataset where we've shown at 36 weeks the ability to improve lung function in IPF patients by over 200ml. And that's something that's quite tremendous and is consistent with this mechanism of action. You know, one question that many ask about anti-fibrotic or potential therapies for IPF is whether the effect will be sustained. And so to see over 36 weeks that you're able to have this effect on IPF patients is quite outstanding. And the consistency and robustness of the dataset is also quite outstanding. Most patients, 65%, have an improvement in lung function, whereas an untreated IPF patient would typically experience a decline in lung function by 180ml. All subgroups are performing above baseline at both mean and median, which is also really reflecting this robustness and consistency across the data set. And I think it's not to be understated that the drug has an excellent safety and tolerability profile. We do not see the gastrointestinal side effects associated with the standard of care and some of the emerging standards of care, such as nausea and diarrhea; furthermore, other side effects like photosensitivity are not present in the V4 molecule and mechanism of action. And I think that this is tremendous because it's something that allows this drug to behave as a frontline therapy for the disease state. It allows it to be combined if that's what's most suitable. And it's also a reflection of the difference between this mechanism and many of the other mechanisms that are pursued where blocking, you know, kind of downstream wound healing processes can also interfere with normal processes to maintain, uh, you know, tissue homeostasis and extracellular matrix. And by adopting a different approach focused on repair and resolution, you can achieve this in a very safe and well-tolerated way, according to the data available to date. And the third point I'll make about our Phase 2a dataset links it back to the first pillar; the biomarkers that we see in the Phase 2a dataset demonstrate the mechanism that we observe in our preclinical datasets. So we see in the IPF patients a trend of decrease in TGF-beta 1, which is a profibrotic cytokine that drives the production of new collagen and fibrosis. And then we also see a significant upregulation in the IPF patients in their blood of MMP-13, a matrix metalloprotease that is responsible for chopping up or digesting existing fibrosis. So basically, we're showing in our dataset biomarkers that suggest we're both stopping or slowing down new fibrosis buildup and getting rid of, digesting, or resolving fibrosis that already exists, which is quite excellent as well. And then the third pillar is really that this next experiment that we've now initiated, this Phase 2b, is the experiment. It is robust, featuring a regulatory or approval endpoint with a 52-week change in forced vital capacity. It is a large study with 270 patients for this patient population. A robust size, it is designed with the commercial label in mind, which is as a front-line therapy that can be combined with the standard of care, and it has a global footprint where we'll be enrolling this study from 14 different countries. So maybe from here I'll step forward and talk about the Phase 2b even a little bit more. Right. So I've mentioned the attributes that make us so excited about this, the robustness, the size. We've also sought to make it very patient-friendly and accessible, both because we want to be focused on ultimately serving the patients, but also because we want to ensure efficient enrollment. So we've really done our best to limit the number of in-person visits at clinical sites, making it easier for patients to participate, while also continuing to engage with the patients to ensure they are doing well in the study. And so we've included a number of virtual, phone, or video visits with the patients throughout the study as well. As I indicated, the robustness includes some dose-response testing where we'll be using the same dose level as in the Phase 2a, 100mg twice daily. But we'll also be exploring a lower dose, 50 mg twice daily, over that 52-week period. Uh, and then maybe if I could speak a little bit more about the powering as well. Right. What we saw in the Phase 2a, which is reflected in the graph on the left in green, is a 200 milliliter improvement in lung function, or over 200 milliliters, when you would expect a 180 milliliter decline in this patient population over 36 weeks. That's a 400 milliliter treatment effect, quite outstanding. What we saw in the Phase 2b, but actually, when we consider how we're powering the Phase 2b, we're doing so quite conservatively in the sense that we're powering the study to detect a stabilization of lung function up to 52 weeks. While it will be quite outstanding if we're able to observe an improvement in lung function, even a stabilization in lung function would both produce a positive clinical result and a blockbuster, multibillion-dollar commercial opportunity, in our view. Thus, it was important for us to power the study conservatively and robustly. And then, as we mentioned, we're targeting 14 countries, approximately 100 clinical sites. The sites are now coming online. As we mentioned, we've received regulatory approval to initiate this study from the US FDA, as well as from other health authorities, and we're looking forward to enrolling patients in due course. So maybe from here, I'll turn it over to Hans to talk a little bit about today's transaction as well.
Thanks for that, Ahmed. So, next slide, please. So the rights issue is approximately 790 million to 2 billion SEK, equivalent to 75 million USD. We have subscription and guaranteed commitments for approximately 80% of the rights issue, corresponding to approximately 626 million SEK. The main purpose of the rights issue is to finance the expanded Phase 2b trial of buloxibutid in IPF, but also to carry out phase three preparatory activities, including process and commercial development. And in addition to that, also for the development of the drug platform using rat models and to extend the cash runway of the company to the first half of 2028. In addition to the rights issue, VICORE PHARMA may carry out a directed issue to selected institutional investors, provided that the rights issue has been subscribed to at least 80% without any utilization of guarantee undertakings. Terms of the rights issue are a 1 to 1 ratio, so one subscription right for every share held on the record date with each subscription right entitling shareholders to subscribe for one new share. The subscription price is $0.07 per share. Next slide please. So we are very happy with the significant support from existing shareholders, which together with management and the support from the board of directors in total sum up to approximately 50% of the rights issue, which is approximately 389 million SEK, which is exceptionally high compared to many other rights issues. Members of the board of Directors and management, including the chairman of the board, have undertaken to subscribe to approximately 2 million SEK in the rights issue due to restrictions on participation of US persons in the rights issue. The CEO, Ahmed Mousa, has undertaken to purchase shares on the market, corresponding to approximately 1 million SEK. Underwriting commitments correspond to approximately 237 million, or 30% of the offering. The underwriting commitments have been secured at a fee of 5% in cash, which is extremely low. A few important dates to keep in mind include the publication of the prospectus on September 18th. The subscription period runs from September 20th until October 4th, and we expect to announce the outcome of the rights issue around October 7th. With that, I hand over to Megan for the Q&A.
Excellent. Thank you, Hans. We will first take questions from those dialing in on the phone, and then we will move to questions from the chat.
If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Dan Xiaoqi from Perito Securities. Please go ahead.
Thank you for taking my questions. Just two broader questions. So you're preparing the Phase 3 package as well. Are you aiming to have basically everything? Also, commercial manufacturing will be ready by the end of the Phase 2b trial, so that we can produce at a commercial scale, at least. And, with regards to the period for the Phase 2b ASPIRE trial, which I assume you don't want to guide specifically, but could we expect all enrollment around year end '25 or early '26? And then the result comes, obviously one year later. And during that period until late '26. Could we expect some other kind of news flow, and what kind of news flow? Thank you.
Yes. Thank you for the questions, Dan. So on your first question regarding commercial preparation. Absolutely. It's very important to start working on the preparatory activities, which encompass a number of aspects. But the most significant aspect is the CMC, or formulation and manufacturing. So actually, this year, we're intending to select the commercial manufacturer for the program and to initiate the scale-up, both in terms of the scale quantity as well as the quality. Further development of the process could be appropriate for a commercial setting, and that takes significant investment, but is necessary to start now because it does take time, and we want to be in exactly the right position, as you suggest, when we're finished with the Phase 2b, to be able to move forward very efficiently and not have to delay any manufacturing or other product development activities. So that is a significant portion of the raise. And it's also a very important portion of the raise, because certainly finishing the Phase 2b and then stopping for some years to undertake those activities would not be acceptable, in terms of both bringing a drug to patients as quickly as possible and from an investment perspective. Your second question was related to the timing of the study. Well, we're not going to formally guide, but I think that the timing you indicated, seeking to enroll patients by the end of 2025, is not unreasonable based on how long it takes. Companies that have conducted studies of similar size with a comparable global footprint. So that’s certainly something. Uh, you know, that's something we could keep in mind as a potential timeline. The last question that you asked is about the news flow between now and then, and I would say that while we have allocated a modest amount of capital towards the early stage platform, we actually think it is going to be quite impactful. And so we're really excited to be continuing to advance early stage programs, including into the clinic, over the time period. We're very excited to be continuing to develop data sets that demonstrate the efficacy of this molecule for IPF as we continue to advance it. Um, and that’s, you know, translational data sets and preclinical data sets that help us characterize the molecule better, including with the standard of care and emerging standards of care. And that'll help us position it commercially as best as possible. We are really pleased and look forward to discussing this further with the community over time. And then also, we're even looking at this mechanism of action and the follow-on molecules that will be advancing to the clinic, as we mentioned in other indications where we think this mechanism has the same transformative potential as it does in IPF. So we're also excited about the things that we're going to be able to discuss with the investor community over time as well. Thanks for your question, Stan. Thank you.
The next question comes from Arvind Kanda of Carnegie. Please go ahead.
Thanks for taking my questions. Um, so I guess you raised roughly 50 million USD last year. And as I understood it, at least, this was with the primary purpose to finance the ASPIRE trial and take the company into 2027. Which should, by most estimates out there. Be a top-line data. So, just sort of wondering what has ended up costing more than initially estimated and whether or not you have changed anything since then in the study design? I'll start there. Yeah.
No, thanks for joining. And thank you for the question, Arvid. Uh, I think first and foremost, the study size was increased. So it went from 200 to 270. And as I alluded to in the presentation, this provides for more robust powering so that we can detect even a stabilization of lung function. That part of the increased powering was also due to new developments that we're seeing in the IPF landscape even after that financing. So in particular, we keep a close eye on how placebo groups should be performing in IPF trials. There were some late-stage IPF trials that had a relatively mild placebo group in terms of lung function decline. And when you see these types of datasets, it points you in the direction of increasing study size to ensure that your study is sufficiently powered to hit its p-value for a particular effect. So, the first component is the size. The second component is really about thinking carefully. You know, the team considers the right level of quality and robustness as we plan forward for the study. Some of that is seen in the details. But the details matter. If you want to create an impactful inflection point that can lead to a commercial launch or facilitate the right discussions with potential strategic partners as well. And so, for example, we're currently targeting up to 30% of the patients enrolled out of the United States and other high-quality jurisdictions. So that's quite important for us as well. And then, you know, another piece of the puzzle is having the appropriate staffing footprint to effectively not only enroll in this study but also to execute the study over the entire course. So, for example, we'll be hiring clinical science liaisons in the different territories that will be conducting the studies. And this allows for efficient execution across it because you want to both enroll the patients and keep the clinical sites and the patients engaged over a one-year study for each patient as they come in. And it's quite important to collect the right dataset to ensure that your patients remain in the study. And this is a challenge for older IPF patients. And so we thought a lot about the details and how to make this study as robust as possible. And that does have an expense. But that expense is exactly worth it. The next point that I'll make is the product development. The CMC is critical, right? And as I mentioned, our current plan is to have the commercial manufacturer selected by the end of this year. And these investments, you know, require capital at the outset. But, you know, we're basically going to be taking that time period between now and the Phase 2b ASPIRE trial to be read out, and we're going to fully take advantage of it in order to have a commercial formulation that's suitable for a launch and for Phase 3.
Right. Okay. Yeah. I mean, all very valid points, but I guess 270 patients were already guided for last year, and, you know, adding. So sorry to interrupt you.
Sorry to interrupt you, Arvind. I joined the company in September. And the plan when I joined in September, which was after the financing, was a 200-patient study. And then we reevaluated that after I joined in September of 2023 and then determined to increase it to 270. And again, one of the factors in that determination was that Galactose had a Phase 2b IPF readout that also came in September of 2023. Uh, so this was after the financing, which was in July of 2023 before I joined the company. Sorry to interrupt you, though.
Okay. No. Don't worry. Okay, I'm just trying to sort of square that up. It still seems like this is, you know, overshooting what it would cost to add those patients by quite a margin. So, is it the CMC that is actually the main component here that was a bit undersized? And what you raised last year.
Yes, I think it's across the board. I think that's right. The additional patients do cost a lot of money. I think that the selection around how you're going to run the study makes a difference, right? It makes a difference what countries you pick and it makes a difference how you do it. Some of those items may not be in the headlines in terms of how we present things, but they do matter in terms of cost and their ultimate impact. And then, yes, absolutely. Also, on the CMC, I mean, the one thing I will say is that if you look at every single other biotech company that's running an IPF study of this size, we are still the most cost competitive. So I have not seen another biotech company run a study like this as cost efficiently as we will, including this financing. So I will say that we're quite fiscally disciplined. So again, if you look at what we said, we did a 50 million USD cash raise last year, or 500 million SEK. Currently, we have, you know, a mid-40s cash position, around 42 million, I believe, as of the end of last quarter. So, we've actually been quite careful with our capital and we're deploying it towards the right aim. But um, quality costs money, but it's worth it in the end; I think that's the top-level message I would give there.
Okay. Yeah. Sure enough, just the last question. Then, do you expect that with the capital you are currently raising, you will be able to meaningfully accelerate the ASPIRE timeline compared to your previous expectations?
That's a great question. I think, you know, Dan had also asked about the general timing. We're not going to formally guide yet. I think that Dan had mentioned, you know, what do you think about enrolling your patients by the end of '25? And I indicated that I think that's not unreasonable. When you look at the other studies that have been conducted, you know, of this size and of this clinical footprint, we'll have to see as we get into the study. But we are looking to find ways to make this enrollment as efficient as possible. So the clinical science liaisons are part of that. The, you know, limiting the number of visits at the clinical sites for the patients is part of that strategy, to be honest with you. Even the nature of buloxibutid—its easy-to-take oral small molecule form—is part of that. So we've tried to make this study as easy as possible. And we've certainly tried to engage with clinical sites and patient communities to make it as exciting as possible. And we'll just have to see how the timing goes. We are also targeting about 100 clinical sites, as I mentioned, which is an increase from some of the previous plans and this also impacts our ability to conduct the study more swiftly.
Okay. Great. Thank you so much. Those were all my questions.
Thank you, Arvid. Appreciate it.
The next question comes from Sushila Hernandez from Van Kempen. Please go ahead. I have two questions, if I may. So, given the number of clinical trials in IPF. Could you elaborate on the efforts that you will be undertaking to fully recruit this study? Have some of the sites already been activated, and what are your key messages shared with the participants? And also, with the Phase 2b powered for disease stabilization, is your assumption that you can move into a single Phase 3 study following a successful Phase 2? Thank you.
Yeah. Hi, Sheila. Great questions. I think you're then perhaps answering your own last question. First, you're asking about the powering of the study. Powering the study, as I said, is for stabilizing the disease under the assumption of a potentially mild placebo arm. Let's see how it enrolls and how it turns out. But a conservative approach to powering the base case is to run a single Phase 3 study. We do not think that we would be required to run two. Certainly, the upside case is that we could persuade the regulatory authorities for some sort of accelerated or conditional approval. This is dependent on the country. And I think it depends on the effect size and the broader IPF landscape. So it's harder to comment further with any certainty right now, but it is certainly something that we will continue to watch and advocate for, with a readout in hand, particularly from a study of this robustness. Sorry, could you mention your other two questions? If I recall.
Yes. Thank you. So, given the number of clinical trials in IPF, which elaborates on the efforts that will be undertaken to fully recruit this study, have some of the sites already been activated, and what are the key messages shared with these participants? Thank you.
Yeah, so, great question. First of all, it starts with country selection. So the countries were selected based on an understanding of which countries would be most amenable to a protocol like this? And also what studies are being run in which countries during which time period. And then that same analysis is applied to the clinical sites as they're selected. So, for example, we have conversations with the clinical sites about what other clinical trials they are enrolling in at a particular time. And of course, it is a rare disease. And patients tend to go to specialized centers. So it's not that you go for clinical sites that don't have IPF patients or don't have other clinical studies, but you make sure that it's within a reasonable range so that you're able to have a good chance of accessing patients. The key messages that we deliver in order to execute on the study, and the ones that we think resonate the most, are first and foremost that this is a very well-tolerated drug. When considering IPF patients offered the opportunity or having expressed an interest in participating in a clinical trial, the notion that their quality of life will not be impaired is attractive for both clinicians and patients. So that's certainly a message that we deliver quite loudly. This drug has now been exposed to over 366 patients and volunteers in various clinical studies and demonstrates a very favorable safety and tolerability profile, including over an extended dosing period. And that is different from a number of the other IPF drugs that are currently being tested. And so I think that's a huge selling point. Not every clinical trial can be superimposed on a standard of care therapy. That we're able to nicely combine with standard of care means that a patient who's taking entacapone can stay on that drug and participate in the clinical trial, and that's attractive both to the physician and to the patient as well. And then, of course, we have this amazing efficacy signal that you see in the Phase 2b ASPIRE trial. Right. So there's not only the well-tolerated therapy, but also the promise or potential to have a disease-modifying effect. And I think that can be quite attractive and exciting for the clinical community and for patients as well. And I think particularly for clinicians that tend to be more scientifically focused, this mechanism is so distinct from the emerging standard of care that it excites a number of physicians who are eager to test it and see if we can indeed achieve a category change in the types of drugs we're developing for IPF, not just a target change. So we're hopeful and optimistic that those items will help us engage quite effectively. As I mentioned, we're bringing sites online now, and the United States will be the first country to have sites online. And I think they're coming online in a matter of, you know, weeks this month. Certainly.
Okay. Thank you.
Yes. Thank you, Sheila.
There are no more questions at this time. So I hand the conference back to the speakers for any written questions.
Excellent. Thank you all so much for the great engagement on the phone. So we've had some good questions coming in here on the chat. And we wanted to start off with one. And maybe Ahmed, could you take the lead on this one? Why did you decide that now is the right time for the company to raise capital?
Yes, I believe there are. There are two key reasons. The first is really the most important when you start a clinical study of this nature, from both an ethical and a corporate perspective. It's our view, as well as the board's, that the trial needs to be fully funded. Right. This involves a great deal of sacrifice on the part of patients who have this terminal disease. And, you know, it's important to ensure that we're able to treat the patients for the entirety of the clinical study and have the readout. I think that also is quite important to many investors. Right. So to ensure that, you know, we can't bring any inflection with only half of the capital needed for a study or just a portion of the capital needed for a study. So it's quite important from our perspective, for a number of reasons, that the study be fully funded from the beginning. And I think the second reason is a little bit more strategic. But I think it's great to be independent of capital needs from the start of the study, drive through the inflection point, and completely remove the financing overhang, which is what we're doing with this transaction.
Thank you, Ahmed. Another question that has come up a few times concerns the curiosity about the involvement of US specialist investors in this capital raise. Hans, can you speak to that?
Yes, sure. We have a policy of not commenting on specific individual investors. However, we have secured subscriptions from a number of investors mentioned in the press release. We would, however, like you to know that some funds are restricted from a legal point of view to provide undertakings.
Great. And another question here is actually more focused on the Phase 2b ASPIRE trial. This person is curious why we are including a 50 milligram cohort, since the side effect profile of the 100 milligram group was excellent. Armin, can you speak to this?
Yeah. So it's a great question. So I think there are two key reasons for that. One is the expectation of health authorities. There are a number of health authorities that, as a requirement in drug development, like to see some exploration of dose. So for example, we've had explicit discussions with the US FDA on the subject and aligned with them on this clinical trial protocol and their expectation to see some exploration of dose and dose response. So that is one reason why we opted for a second dose in our Phase 2b study. The second reason is, if you might recall, in the Phase 2a, we did have a minority of patients, 19%, who had some hair thinning or hair loss. It was mild to moderate and it was reversible. And because IPF is a fatal disease, you know, largely affecting older men. We believe the side effect profile will ultimately be manageable, and it will be a very attractive drug. At the same time, of course, if we can make this drug even easier for people to take and even more attractive by having a lower dose that doesn't have that effect, that would be quite outstanding as well.
Thank you, Ahmed. So, we've actually gotten through quite a number of the questions in the chat. So I think this is a good place to conclude the call. So I will turn it over to you for any closing remarks.
Well thank you, Megan, and thank you all for your attention and for your support. And we're really looking forward to initiating and successfully executing this clinical trial, delivering an incredible return for investors, hopefully with a positive readout, as well as a transformational therapy for IPF patients. And I hope you have a great afternoon and a great day.



















